Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Tesamorelin is FDA-approved to reduce excess visceral adipose tissue in HIV-associated lipodystrophy and is studied for broader body-composition, NAFLD, and cognitive effects via GH/IGF-1 axis modulation1893, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.
While Tesamorelin works as a full-length 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that binds GHRHR, activating cAMP/PKA signaling to increase endogenous GH and IGF-1, with improved stability versus native GHRH182893102, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.
Tesamorelin
GHRH
Thymosin Beta-4
TMSB4X
Tesamorelin and Thymosin Beta-4 are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Cardiovascular health contexts, while Tesamorelin is more of a hormone peptide and Metabolic peptide and Thymosin Beta-4 is better described as a signal peptide and Cytokine peptide. Their biological logic is quite different: Tesamorelin is a receptor agonist, whereas Thymosin Beta-4 is a signaling modulator and a protein interaction inhibitor. Tesamorelin has a more synthetic analog origin, while Thymosin Beta-4 is closer to natural endogenous background and their development context also differs, with Tesamorelin approved while Thymosin Beta-4 is in Clinical phase 2. Tesamorelin takes the form of a peptide conjugate, whereas Thymosin Beta-4 is closer to a linear peptide, Tesamorelin carries amidation features, while Thymosin Beta-4 instead reflects acetylation changes; while their sequence patterns also diverge, with Tesamorelin showing alpha-helical domain features and Thymosin Beta-4 showing protein-mimetic sequence features.